Close

UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper T

Go back to UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper T
(NASDAQ: URGN) Delayed: 15.00 +0.04 (0.27%)
Previous Close $14.96    52 Week High
Open $14.92    52 Week Low
Day High $15.25    P/E N/A 
Day Low $14.56    EPS
Volume 200,826